vs

Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Inogen Inc (INGN). Click either name above to swap in a different company.

HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $68.6M, roughly 1.4× Inogen Inc). On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 3.4%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 4.2%).

Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.

Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.

HIVE vs INGN — Head-to-Head

Bigger by revenue
HIVE
HIVE
1.4× larger
HIVE
$93.1M
$68.6M
INGN
Growing faster (revenue YoY)
HIVE
HIVE
+215.1% gap
HIVE
218.6%
3.4%
INGN
Faster 2-yr revenue CAGR
HIVE
HIVE
Annualised
HIVE
102.2%
4.2%
INGN

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
HIVE
HIVE
INGN
INGN
Revenue
$93.1M
$68.6M
Net Profit
$-91.3M
Gross Margin
-27.1%
51.4%
Operating Margin
-13.6%
Net Margin
-98.1%
Revenue YoY
218.6%
3.4%
Net Profit YoY
-234.0%
EPS (diluted)
$-0.38
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIVE
HIVE
INGN
INGN
Q4 25
$93.1M
$68.6M
Q3 25
$87.3M
$79.1M
Q2 25
$45.6M
$79.2M
Q1 25
$68.5M
Q4 24
$29.2M
$66.3M
Q3 24
$22.6M
$74.9M
Q2 24
$32.2M
$74.4M
Q1 24
$63.1M
Net Profit
HIVE
HIVE
INGN
INGN
Q4 25
$-91.3M
Q3 25
$-15.8M
$-5.3M
Q2 25
$35.0M
$-4.2M
Q1 25
$-6.2M
Q4 24
$68.2M
Q3 24
$80.0K
$-6.0M
Q2 24
$-18.3M
$-5.6M
Q1 24
$-14.6M
Gross Margin
HIVE
HIVE
INGN
INGN
Q4 25
-27.1%
51.4%
Q3 25
4.7%
52.2%
Q2 25
-13.6%
52.2%
Q1 25
53.1%
Q4 24
-43.7%
54.7%
Q3 24
-66.1%
55.2%
Q2 24
-7.4%
57.4%
Q1 24
54.5%
Operating Margin
HIVE
HIVE
INGN
INGN
Q4 25
-13.6%
Q3 25
-9.0%
Q2 25
-7.7%
Q1 25
-11.2%
Q4 24
-17.2%
Q3 24
-10.4%
Q2 24
-9.5%
Q1 24
-25.8%
Net Margin
HIVE
HIVE
INGN
INGN
Q4 25
-98.1%
Q3 25
-18.1%
-6.7%
Q2 25
76.8%
-5.2%
Q1 25
-9.0%
Q4 24
233.2%
Q3 24
0.4%
-8.0%
Q2 24
-56.7%
-7.5%
Q1 24
-23.1%
EPS (diluted)
HIVE
HIVE
INGN
INGN
Q4 25
$-0.38
$-0.26
Q3 25
$-0.07
$-0.20
Q2 25
$0.18
$-0.15
Q1 25
$-0.25
Q4 24
$0.52
$-0.41
Q3 24
$0.00
$-0.25
Q2 24
$-0.17
$-0.24
Q1 24
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIVE
HIVE
INGN
INGN
Cash + ST InvestmentsLiquidity on hand
$103.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$559.3M
$192.2M
Total Assets
$624.0M
$298.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIVE
HIVE
INGN
INGN
Q4 25
$103.7M
Q3 25
$106.5M
Q2 25
$103.7M
Q1 25
$118.9M
Q4 24
$40.5M
$113.8M
Q3 24
$31.7M
$105.7M
Q2 24
$97.9M
Q1 24
$107.4M
Stockholders' Equity
HIVE
HIVE
INGN
INGN
Q4 25
$559.3M
$192.2M
Q3 25
$624.6M
$197.2M
Q2 25
$560.5M
$199.5M
Q1 25
$198.0M
Q4 24
$430.9M
$173.9M
Q3 24
$275.5M
$185.4M
Q2 24
$268.6M
$187.6M
Q1 24
$191.9M
Total Assets
HIVE
HIVE
INGN
INGN
Q4 25
$624.0M
$298.6M
Q3 25
$693.0M
$307.0M
Q2 25
$628.7M
$312.0M
Q1 25
$308.4M
Q4 24
$478.6M
$296.2M
Q3 24
$334.7M
$306.2M
Q2 24
$308.9M
Q1 24
$315.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIVE
HIVE
INGN
INGN
Operating Cash FlowLast quarter
$46.0M
$-943.0K
Free Cash FlowOCF − Capex
$-1.9M
FCF MarginFCF / Revenue
-2.8%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-13.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIVE
HIVE
INGN
INGN
Q4 25
$46.0M
$-943.0K
Q3 25
$-10.6M
$2.2M
Q2 25
$10.2M
$4.3M
Q1 25
$-16.8M
Q4 24
$-28.5M
$-3.0M
Q3 24
$-2.2M
$7.0M
Q2 24
$-4.4M
$6.7M
Q1 24
$-4.7M
Free Cash Flow
HIVE
HIVE
INGN
INGN
Q4 25
$-1.9M
Q3 25
$1.6M
Q2 25
$3.7M
Q1 25
$-17.1M
Q4 24
$-55.5M
$-3.3M
Q3 24
$-34.7M
$5.3M
Q2 24
$6.6M
Q1 24
$-6.1M
FCF Margin
HIVE
HIVE
INGN
INGN
Q4 25
-2.8%
Q3 25
2.0%
Q2 25
4.6%
Q1 25
-24.9%
Q4 24
-189.9%
-5.0%
Q3 24
-153.4%
7.1%
Q2 24
8.9%
Q1 24
-9.6%
Capex Intensity
HIVE
HIVE
INGN
INGN
Q4 25
1.4%
Q3 25
0.7%
Q2 25
0.9%
Q1 25
0.4%
Q4 24
92.5%
0.5%
Q3 24
143.9%
2.2%
Q2 24
0.1%
Q1 24
2.1%
Cash Conversion
HIVE
HIVE
INGN
INGN
Q4 25
Q3 25
Q2 25
0.29×
Q1 25
Q4 24
-0.42×
Q3 24
-26.94×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HIVE
HIVE

Segment breakdown not available.

INGN
INGN

Other$36.1M53%
Non Us$32.5M47%

Related Comparisons